Robert B. Den, MD, discusses bone-targeting agents in prostate cancer and the potential future of combinations.
Veda Giri, MD, discusses the developing role of genetic testing for the screening and management of patients with prostate cancer.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding the option of a 4-week dosing schedule to the label for nivolumab for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC).
The FDA has granted enfortumab vedotin a breakthrough therapy designation for patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint therapy.
Leonard G. Gomella, MD, shares his insight on this year's expected advances in the field of prostate cancer.
The current standard-of-care therapy for patients with clear cell renal cell carcinoma is sunitinib, but many patients relapse or don't have responses to the drug.
The FDA has granted a priority review to a supplemental new drug application (sNDA) for enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.
Ani S. Balmanoukian, MD, discusses developments in genitourinary malignancies with promising immunotherapy breakthroughs in renal cell carcinoma and urothelial carcinoma.
The FDA has granted a breakthrough therapy designation to erdafitinib for the treatment of metastatic urothelial carcinoma.
Stephen J. Freedland, MD, shares his insight on how to counsel patients with prostate cancer on the benefits of leading a healthier life.